Stockreport

Longeveron's CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer's Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer'...

Longeveron Inc. - Class A Common stock  (LGVN) 
PDF announced that it has been accepted for a Featured Research Oral Presentation to present the Company's CLEAR MIND Phase 2a study results. CLEAR-MIND is a Phase 2a random [Read more]